11,13-modified saxitoxins for the treatment of pain
US11236097B2 · kind B2 · utility
2Cited by
6References
29Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 29, 2018 |
| Grant date | Feb 1, 2022 |
| Priority date | — |
| Expiry date | Mar 29, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.